Stella Pharma (4888) · InitiativeAdvanced
Support for an Investigator-Initiated Specified Clinical Research Study for Recurrent Breast Cancer
First written in FY2024-Q1. 1 of 2 entries say "Advanced", first in FY2025-H1. Latest entry: FY2025-H1.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Support for an investigator-initiated specified clinical study on recurrent breast cancerA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025-H1AdvancedAnnual report
「A paper on an investigator-initiated specified clinical study for recurrent breast cancer conducted at Edogawa Hospital, to which we provide our drug product, was published in the electronic edition of Cureus under the title “The Effects of Boron Neutron Capture Therapy on the Lungs in Recurrent Breast Cancer Treatment,”」
The results of an investigator-initiated specified clinical study for recurrent breast cancer conducted at Edogawa Hospital were published as a paper in the electronic edition. - FY2024-Q1First statedAnnual report
「Entered into an agreement to cooperate in an investigator-initiated specified clinical study for recurrent breast cancer conducted at Edogawa Hospital, Social Welfare Corporation Jinseisha.」
The cooperation agreement with Edogawa Hospital for an investigator-initiated specified clinical study for recurrent breast cancer is described as a new initiative.